Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) ; volume:79 ; number:4 ; day:11 ; month:3 ; year:2017 ; pages:651-660 ; date:4.2017
Cancer chemotherapy and pharmacology ; 79, Heft 4 (11.3.2017), 651-660, 4.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Yamazaki, Naoya
- Contributor
-
Takenouchi, Tatsuya
Fujimoto, Manabu
Ihn, Hironobu
Uchi, Hiroshi
Inozume, Takashi
Kiyohara, Yoshio
Uhara, Hisashi
Nakagawa, Kazuhiko
Furukawa, Hiroshi
Wada, Hidefumi
Noguchi, Kazuo
Shimamoto, Takashi
Yokota, Kenji
SpringerLink (Online service)
- DOI
-
10.1007/s00280-016-3237-x
- URN
-
urn:nbn:de:1111-201704132793
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamazaki, Naoya
- Takenouchi, Tatsuya
- Fujimoto, Manabu
- Ihn, Hironobu
- Uchi, Hiroshi
- Inozume, Takashi
- Kiyohara, Yoshio
- Uhara, Hisashi
- Nakagawa, Kazuhiko
- Furukawa, Hiroshi
- Wada, Hidefumi
- Noguchi, Kazuo
- Shimamoto, Takashi
- Yokota, Kenji
- SpringerLink (Online service)
Other Objects (12)
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
3475
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Nr. 3475
Nr. 3475
Nr. 3475
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Gebäudebuch 2995-3475
Nr. S 3475
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
3475
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Nr. 3475
Nr. 3475
Nr. 3475
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Gebäudebuch 2995-3475
Nr. S 3475
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
3475
KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
Nr. 3475
Nr. 3475
Nr. 3475
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Pembrolizumab plus Radiochemotherapie bei lokal fortgeschrittenem Zervixkarzinom – die prospektive, randomisierte KEYNOTE-A18-Phase-3-Studie
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
Gebäudebuch 2995-3475